Urothelial Carcinoma Clinical Trials in Philadelphia, Pennsylvania
13 recruitingPhiladelphia, Pennsylvania
Showing 1–13 of 13 trials
Recruiting
Phase 2Phase 3
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial CarcinomaStage IV Bladder Urothelial Carcinoma AJCC v7Muscle Invasive Renal Pelvis Urothelial Carcinoma+4 more
National Cancer Institute (NCI)992 enrolled493 locationsNCT05987241
Recruiting
Phase 2
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Muscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8
National Cancer Institute (NCI)111 enrolled134 locationsNCT07061964
Recruiting
Phase 2Phase 3
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
Renal Pelvis and Ureter Urothelial Carcinoma
National Cancer Institute (NCI)249 enrolled258 locationsNCT04628767
Recruiting
Phase 1Phase 2
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
Urothelial CarcinomaBladder Cancer
Noah Hahn, M.D.55 enrolled12 locationsNCT03317158
Recruiting
Phase 1
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Gastric AdenocarcinomaBladder CancerMesothelioma+7 more
IDEAYA Biosciences260 enrolled10 locationsNCT07277413
Recruiting
Phase 1Phase 2
Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
Low-grade Upper Tract Urothelial Carcinoma
Ferring Pharmaceuticals20 enrolled7 locationsNCT06668493
Recruiting
Phase 2
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Muscle Invasive Bladder Urothelial Carcinoma
Matthew Galsky47 enrolled5 locationsNCT06809140
Recruiting
Phase 2
Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma
Metastatic Urothelial CarcinomaUnresectable Urothelial CarcinomaAdvanced Urothelial Carcinoma
Fox Chase Cancer Center97 enrolled1 locationNCT07221942
Recruiting
Not Applicable
Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy
Urothelial CarcinomaMuscle-Invasive Bladder CarcinomaBladder Cancer+3 more
Thomas Jefferson University70 enrolled2 locationsNCT07234968
Recruiting
Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)
Urothelial CarcinomaMuscle Invasive Bladder Urothelial CarcinomaNon-Muscle Invasive Bladder Urothelial Carcinoma
Fox Chase Cancer Center92 enrolled2 locationsNCT06396533
Recruiting
Phase 2
Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma
Urothelial Carcinoma
Fox Chase Cancer Center55 enrolled2 locationsNCT07043972
Recruiting
Phase 1
Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer
Bladder CancerUrothelial Carcinoma Bladder
Abramson Cancer Center at Penn Medicine10 enrolled1 locationNCT06586255
Recruiting
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
Urothelial CarcinomaRenal Cell CarcinomaBladder Cancer+2 more
Fox Chase Cancer Center16 enrolled1 locationNCT03291028